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Abstract 
Rheumatoid Arthritis (RA) is an inflammatory autoimmune disease which causes 
joint destruction. RA pathogenesis involves citrullinated peptides binding to the shared 
epitope (SE) during autoantigen presentation, and subsequent Anti-Citrulline Antibody 
(ACA) production.  Their target, citrulline, is very similar to homocitrulline.   
The main objective of this study was to investigate anti-homocitrulline immune 
responses in RA.  Specifically, it investigated if: i) Anti-Homocitrulline Antibodies 
(AHA) were RA specific by screening patients with various inflammatory rheumatic 
diseases and healthy individuals. ii) ACA also bound homocitrulline by affinity 
purification and characterization.  iii) anti-homocitrulline immune responses involved the 
SE by computer modelling and immunization of mice. 
Results showed that AHA were common in RA only, some ACA also bound 
homocitrulline, and the SE could accommodate homocitrulline but did not restrict anti-
homocitrulline responses in mice.  In conclusion, AHA are specific to RA and some ACA 
cross-react with homocitrullinated targets.  The SE is not essential for anti-homocitrulline 
responses. 
 
Keywords: Rheumatoid Arthritis, Homocitrulline, Citrulline, Autoantibodies, 
 Cross-reactivity, Shared Epitope 
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1.1 Immunology overview 
The immune system is critical for the human body’s development, maintenance, 
and protection from foreign entities.  It is broadly separated into two different categories: 
innate and adaptive immunity.  In the context of infection, the former plays an important 
role in prevention and the initial, general response.  Alternatively, the adaptive immune 
system recognizes specific targets to promote elimination of pathogens as well as 
sustained protection from re-infection through immunological memory. 
1.1.1 Innate immunity 
The innate immune system is comprised of any cellular and humoral factors that 
act as a first line of defense to prevent or combat disease and infection.  The major cells 
involved are neutrophils, macrophages (1), natural killer cells (2), and dendritic cells (3-
4).  The innate immune system does not recognize specific regions of invading pathogens 
or unhealthy tissue, but rather binds common structures known as Pathogen-Associated 
Molecular Patterns (PAMPs) (5) or Damage-Associated Molecular Patterns (DAMPs) 
(6).  PAMPs and DAMPs are recognized by various proteins known as Pattern 
Recognition Receptors (PRRs) such as the Toll-Like Receptors (TLRs) (5). The binding 
of PAMPs/DAMPs to membrane bound or intracellular PRRs triggers the expression of 
inflammatory genes leading to the release of signaling proteins (cytokines) and cellular 
attractants (chemokines) (7). The subsequent induction of inflammation, observed 
clinically as heat, swelling, redness, and pain, occurs very quickly.  Another mechanism 
for the induction of inflammation is through biochemical cascades involving soluble 
plasma proteins known as complement factors (8).  Complement proteins are the major 
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humoral component of innate immunity and can aid the immune response by coating 
foreign invaders (9).  The coating of complement proteins on foreign cell bodies can 
promote membrane instability leading to cell death and improve immune recognition 
(10). 
During inflammation, one of the primary ways infectious agents are removed 
from the body after recognition is through phagocytosis.  Phagocytosis is a mechanism by 
which particles are engulfed by the cell.  Pathogens and damaged tissues are bound and 
surrounded by host cell membrane forming an intracellular vesicle known as a 
phagosome (11).  The phagosome then binds to a lysosome which drops the pH of the 
compartment (12). This triggers destruction of the pathogen by hydrolytic enzymes (13) 
and reactive oxygen species (14).  Phagocytosis is not only important for innate immunity 
but it is also important for the adaptive immune system, as it allows exposure to foreign 
peptides and proteins (immunogens) for which specific adaptive immune responses can 
be mounted against (15). 
1.1.2 Adaptive immunity 
In contrast to the innate immune system, the adaptive immune system takes time 
to initiate a response and the response is specific since it targets unique peptide/protein 
sequences and structures (epitopes). These responses can also provide long-term 
continued protection from re-exposure to the same entity through the generation of 
memory cells.  Adaptive immunity is divided into two different components; T cell 
mediated cellular immunity, and B cell mediated humoral immunity. 
1.1.2.1 T cells 
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T cells are divided into two different, major subsets, CD4+ and CD8+ (16).  Each 
individual T cell expresses T cell antigen receptors with a unique variable region that is 
generated by the genetic recombination of genomic sequences during development (17). 
An individual has a large repertoire of T cells with different antigen specificities and 
through a process known as “clonal selection,” (18) T cells which bind their cognate 
peptide become activated.  T cell receptors recognize foreign peptides in the context of 
Major Histocompatibility Complex (MHC) molecules (19-21).  In a process termed 
antigen presentation, peptides from degraded proteins are bound to MHC molecules and 
exported to the surface of cells to be recognized by T cells (22-23).  CD8+ T cells 
recognize peptides that are bound to MHC class I molecules which are expressed by 
every nucleated cell in the body (24).  Typically, intracellular proteins are digested and 
loaded onto MHC class I molecules through what is known as the “endogenous 
pathway.”  This allows CD8+ T cells to recognize and destroy infected or dysplastic host 
cells (25-26).  CD4+ T cell antigen receptors, on the other hand, recognize peptides 
bound to MHC class II molecule (27-29).  MHC class II molecules are found on 
specialized Antigen Presenting Cells (APCs), such as macrophages and dendritic cells.  
They bind to phagocytosed extracellular peptides generated through the “exogenous 
pathway” and present these peptides to CD4+ T cells which results in CD4+ T cell 
activation (30).  Activated CD4+ T cells can then enhance killing by phagocytes (31) and 
promote B cell responses (32). 
1.1.2.2 B cells 
B cells are responsible for the humoral response of adaptive immunity.  Like T 
cells, each B cell expresses B cell antigen receptors with a unique variable region (33) 
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that is generated by the genetic recombination of genomic sequence segments during 
development (34-36).  Also similar to T cells, B cells undergo clonal selection in which 
cells of the diverse repertoire that encounter their cognate target are activated (37-38).  B 
cell antigen receptors, however, bind to peptides or complete proteins without MHC 
restriction.  The protein region that an antibody binds is known as an epitope or antigenic 
determinant.  When a B cell encounters and binds its antigen, it becomes activated, 
proliferates (39), and further differentiates into a plasma cell that secretes a soluble form 
of its membrane B cell antigen receptor, known as immunoglobulins (Ig) or antibodies 
(40-41).  Like the membrane receptor, each soluble Ig molecule is comprised of two 
identical variable regions that can bind antigen as well as a constant region (42-43).  The 
constant region of antibodies can be bound by protein and specific cell receptors (44).  
There are five different classes of Ig which differ in respect to their constant regions and 
thus, effector molecule interactions.  The five different isotypes are IgA, IgD, IgE, IgG, 
and IgM (45-47).  Membrane bound B cell antigen receptors are IgM and IgD (48) but 
during B cell activation and proliferation, daughter cells can switch isotypes to IgA, IgE, 
or IgG while maintaining their variable region and binding specificity (49).  IgG is the 
most abundant isotype circulating in the human body and, therefore, plays a major role in 
controlling infection.  Antibody class switching typically requires signalling from 
activated CD4+ T cells (50-51) and the isotype of the antibody determines its potential 
effector functions and interactions. 
Upon binding and coating of its target, secreted Ig can result in functional 
neutralization, improved immune recognition and phagocytosis, complement fixation, 
and the formation of antigen:antibody immune complexes (52).  Antigen:antibody 
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binding relies upon numerous non-covalent bonds and the affinity by which an antibody 
can bind its target depends upon the net attractive and repulsive forces.  Hydrogen bonds, 
salt bridges, hydrophobic forces and van der Waals interactions are all important for 
overall affinity and specificity.  Thus, not only the chemical properties of the targeted 
amino acids such as charge are important, but also the structural conformation or shape of 
the targeted region (53-54).  Although antibodies bind their target with high specificity 
and affinity, some are capable of binding multiple targets.  Antibodies binding to targets 
other than the original immunogen are known as “cross-reactive.” (55-56)   Even when 
binding the original, immunogenic antigen, an individual’s naive B cell repertoire does 
not usually include antibodies which can bind with high affinity.  As an immune response 
progresses, however, antibody responses can undergo affinity maturation which increases 
antibody binding affinity through somatic hypermutation of B cell clone variable genes 
(57-58).  High affinity recognition by antibodies helps to ensure efficient clearance of 
foreign pathogens. 
1.2 Tolerance and autoimmunity 
The immune system  must be able to initiate immune responses against pathogens 
or non-self  proteins while leaving healthy tissue unharmed.  The ability to discriminate 
between foreign entities and native host proteins is important for both B and T cells and 
is known as tolerance.  Self tolerance is divided into two major categories: central and 
peripheral.  Central tolerance for B and T cells is achieved through negative selection 
during development in the bone marrow (59-60) and thymus (26, 61), respectively.  
During this process, cells which bind self targets with high affinity are eliminated by 
programmed cell death known as apoptosis (62-64).  Some auto-reactive clones may 
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escape negative selection however, especially those that only weakly recognize self 
proteins (65-66).   
Peripheral tolerance allows control of immune responses throughout the body 
after B and T cell development.  Self reactive clones which were not negatively selected 
or which did not have their cognate self-antigen expressed in the thymus or bone marrow 
can be controlled by multiple mechanisms. T regulatory (Treg) cells can control localized 
immune responses in areas of inflammation (67-68).  Also, tolerance can be induced 
simply by the amount of exposure to antigens.  Self antigens are usually exposed to the 
immune system consistently at high levels while in the case of infection, immunogens are 
available in an acute pattern where availability peaks early.  This distinction can promote 
an altered, inactive immune cell state known as anergy to prevent responses against self 
proteins (69). 
When the ability of adaptive immune responses to distinguish self from non-self 
is compromised, and immunological tolerance is broken, autoimmune disease occurs.  
Autoimmunity can be triggered by infection/injury (70-72).  The inflammation which 
ensues can cause the activation of self-reactive clones which escaped central tolerance 
(73).  Infection can also trigger autoimmunity through a process known as molecular 
mimicry.  If a bacterial or viral antigen is unique enough to trigger an immune response, 
but the target resembles a self protein, cross-reactivity can develop and progress into an 
autoimmune response (74-75). 
Another mechanism which can trigger autoimmune responses is immune reaction 
to altered-self (76).  This is exemplified by healthy responses to tumour cells.  Cancerous 
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mutations lead to the expression of proteins that are different from native, self proteins 
and normal immune responses lead to the elimination of these cells due to their novel 
immunogenic epitopes.  Instead of mutation, however, post-translational modification can 
induce autoimmunity in otherwise healthy tissue (77).  The modification of native 
proteins due to enzymatic modification or chemical insult occurs throughout the body and 
proteins with longer half-lives are likely to accumulate more post-translational 
modifications due to their longer “lifespan.”  As with cancerous mutation, these protein 
modifications generate structurally and chemically unique areas which can be detected 
and targeted by the immune system (78).  If the modification consistently generates 
adequate amounts of targets in tissues, and the individual has the genetic capacity to 
mount a response against the modified protein, an autoimmune response can be 
maintained. 
1.3 Rheumatoid Arthritis (RA) 
RA is an autoimmune disease characterized by inflammation of the joints leading to 
tissue destruction.  RA affects approximately 1% of the world’s population, occurs more 
frequently in women and is a serious cause of morbidity in Canada as well as worldwide.  
In the RA joint, inflammation and hyperplasia of the joint synovium can be observed 
with excess joint fluid causing swelling.  There is also formation of abnormal tissue 
known as pannus and the infiltration of immune cells such as neutrophils, macrophages, 
B cells, and T cells.  Progression of the disease can lead to loss of protective cartilage, 
bone erosion, and eventually loss of joint function.  Inflammation in the lungs, eyes and 
heart, including increased atherosclerosis can also accompany RA.  It is well documented 
that genetic and environmental factors are involved in the development of RA (79-82).  
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The major genetic risk factors are MHC class II genes encoding the Shared Epitope (SE).  
The PTPN22 gene which encodes a tyrosine kinase important for T and B cell responses 
is also linked to RA, however, it is associated with other autoimmune diseases as well 
(83-85) so it is likely involved in the general development of autoimmunity rather than 
the specific pathogenesis of RA.  The autoimmune responses in RA involve T and B cells 
that lead to the production of autoantibodies. 
Antibodies known to be associated with RA are Rheumatoid Factor (RF) and 
Anti-Citrullinated Protein/Peptide Antibodies (ACPA). In 2010 Mydel et al. 
demonstrated the presence of Anti-Homocitrullinated Protein/Peptide antibodies (AHPA) 
in RA (86). While RF and ACPA have been extensively studied, little is known about 
these recently discovered AHPA in RA. 
1.3.1 Rheumatoid Factor (RF) 
The first autoantibody identified in RA was RF, an antibody which binds to the 
constant region of human IgG (87).  Therefore, RF can form immune complexes with 
IgG and also increase immune complex formation by binding and cross-linking pre-
existing antigen:IgG antibody complexes.  RF is most commonly identified as the IgM or 
IgA isotype and has been associated with increased risk of RA with a sensitivity of 60-
80% (88-90).  Its involvement in RA pathogenesis has been questioned, however, as RF 
is not unique to this disease.  It can be detected in other autoimmune diseases such as 
Sjögren’s syndrome and Systemic Lupus Erythematosus (SLE), and even in healthy 
individuals (91). 
1.3.2 Anti-Citrullinated Protein/Peptide Antibodies (ACPA) 
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Anti-Citrullinated Protein/Peptide Antibodies (ACPA) are antibodies which bind to 
proteins or peptides that have undergone the post-translational modification known as 
citrullination (described in 1.3.2.1)  Unlike RF, antibodies which target citrullinated 
antigens are highly specific for RA (>95%) (90).  ACPA were originally identified as 
antibodies that bound to the protein filaggrin in epithelial tissue (92-93) which is not a 
RA-relevant antigen. It is now well documented that the same anti-filaggrin antibodies 
recognize citrullinated fibrinogen (94) which is a RA-relevant antigen because: i) 
antibodies to it are highly specific for RA (94-95); ii) half of ACPA positive RA patients 
have circulating citrullinated fibrinogen:IgG antibody complexes (96);  iii) it is present in 
inflamed RA joints (97); and iv) immunization with it induces arthritis in DR4 
Transgenic (Tg) mice expressing the SE (98).  Human fibrinogen is a conserved, 
hexameric protein that is composed of a pair of the α, , and γ chain (Figure 1.1) (99) and 
contains 79 arginines that potentially can be citrullinated.  
Other identified targets of ACPA include: i) citrullinated collagen II - an extracellular 
matrix protein that is abundant in cartilage (100-101); ii) citrullinated α-enolase - an 
enzyme found in most tissues (102); and iii) citrullinated vimentin - an intracellular 
cytoskeletal protein (103). Citrullinated vimentin was originally described as Sa antigen 
(104-105). These other citrullinated targets are also found in the joints of RA patients (94, 
102, 104-105).   
ACPA, which comprise antibodies to these targets, are commonly detected using 
cyclic citrullinated peptide (CCP2), a surrogate citrullinated antigen that is not present in 
the body.  The specificity of antibodies binding to CCP2 for RA is >95% and its 
sensitivity is 50-70% (90, 106-107).  A citrullinated peptide, JED, with similar sensitivity  
11 
 
 
 
 
 
 
 
   
Figure 1.1  Human fibrinogen X-ray crystal structure.  Ribbon diagram of the 
structure of human fibrinogen obtained by of the X-ray crystallography and viewed in 
PyMol (PDB structure 3GHG) (99). 
 
 
12 
 
 
and specificity for RA as CCP2 has been developed in this laboratory (108-109).  JED is 
a proprietary synthetic, cyclic peptide that is 18 amino acids in length with C-terminal 
amidation.  9/18 residues are citrulline and 2/18 are cysteine to facilitate cyclization 
through disulphide bond formation.  JED can capture anti-CCP2, anti-citrullinated 
fibrinogen, and anti-mutated citrullinated vimentin antibodies and thus, ACPA.  
Therefore, JED peptide is a critical reagent for ACPA purification and characterization of 
these antibodies (108). 
1.3.2.1 Citrullination 
ACPA targets are generated by citrullination which is the post-translational 
deimination of arginine and generates the amino acid citrulline.  The deimination reaction 
is catalyzed by the Ca
2+ 
dependant intracellular enzyme Peptidyl Arginine Deiminase 
(PAD) (110).  During the reaction, an amine of arginine’s guanidine functional group is 
converted to a carbonyl, generating the functional ureido group which is found on 
citrulline (Figure 1.2A).  Thus, the modification effectively neutralizes the positive 
charge that arginine has at neutral pH, producing an uncharged but polar side-chain that 
has an increased affinity for the SE which is commonly found in RA. 
There are five different PAD enzymes encoded by the human genome which suggests 
that citrullination is an important physiological process. It has been shown that 
citrullination plays an important role in Neutrophil Extracellular Trap (NET) release by 
neutralizing positively charged histones to facilitate DNA dissociation and also in 
ribosome assembly by competing with methylation (111-112).  Supporting the role of 
PAD enzyme in RA, some PAD variants have been identified as genetic traits linked to  
13 
 
 
 
 
 
 
 
  
Figure 1.2  Citrullination and homocitrullination.  Citrulline is generated 
enzymatically from arginine (A), and homocitrulline is generated chemically from lysine 
(B).  The identical ureido groups are indicated with a red box.  
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RA.  Citrullination has been shown to occur during the process of apoptosis (113-114) 
which involves influx of calcium that is necessary for PAD activation. Thus, intra-
cellular proteins such as vimentin can be citrullinated during this process and exposed on 
the surface of apoptotic blebs.  During apoptosis, PAD enzyme can also be released to 
citrullinate extracellular proteins in the surrounding tissue, such as fibrinogen and 
collagen.  This process can occur in neutrophils and macrophages during inflammation 
(114-115).  If citrullinated proteins/peptides are not cleared efficiently, these post-
translationally modified proteins can be recognized by the immune system and trigger 
immune  responses that lead to the production of ACPA.  The target of ACPA, citrulline, 
has been shown to be increased in the RA joint as detected by both mass spectrometry 
and immunohistochemistry using Anti Modified Citrulline (AMC) antibodies. 
1.3.2.2 ACPA  and the SE 
The major heritable risk factors for RA are genes encoding MHC class II 
molecules with the Shared Epitope (SE).  Specifically, the SE is linked to the production 
of ACPA (79).  The SE is a consensus amino acid sequence (glutamine/arginine, 
lysine/arginine, arginine, alanine, and alanine) located in the peptide binding groove of 
MHC class II molecules (116).  The SE forms a positively charged P4 binding pocket of 
the MHC molecule.  Hill et al. in the laboratory of Dr. Ewa Cairns showed that the SE 
has an increased affinity for peptides which have polar amino acids at this position 
compared to a positive charge (116). Peptides with a positively charged amino acid at this 
position are repelled due to the like charge, however, an amino acid such as citrulline 
binds to the SE expressed on MHC class II molecules with high affinity.  This can 
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facilitate an immune response which leads to production of ACPA (116-117) (Figure 
1.3).  
1.3.2.3 ACPA and environmental factors 
The role of environmental risk factors in the development of RA is not well 
understood.  The primary risk factor which has been identified is smoking (79, 118).  
Smoking has been shown to promote citrullination in the lungs and was shown to be 
associated with ACPA production in RA (79, 119). 
An alternative environmental risk factor for RA is infection.  Exposure to Epstein-
Barr virus (120), Hepatitis B and C viruses (121-122), and Human Parvovirus B19 (123) 
have been shown to be associated with RA.  In addition to triggering inflammatory 
responses in the presence of auto-reactive T and B cell clones and/or citrulline, it is 
thought that these infections could contribute to the development of RA through antigenic 
mimicry.  In such cases, pathogen epitopes which are targeted by the immune system 
resemble host proteins.  Such an observation has been made in the case of periodontitis, 
which is linked to RA.  In periodontitis, infection of the oral cavity by Porphyromonas 
gingivalis triggers inflammation and immune responses (102).  P. Gingivalis is the only 
known bacterium to express a PAD enzyme.  Therefore, infection can lead to exposure to 
citrullinated bacterial protein, specifically α-enolase (102).   This can trigger an antibody 
response that is cross-reactive with the human form of citrullinated α-enolase, indirectly 
causing ACPA production leading to RA development. 
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Figure 1.3  Citrullination promotes binding to the SE leading to ACPA 
production.  Peptides with positively charged arginine at the P4 position are repelled by 
the positively charged SE (Left) and do not trigger an immune response.  Conversion to a 
polar citrulline residue through citrullination increases affinity for the SE (Right), 
resulting in peptide binding and a subsequent immune response that leads to ACPA 
production.  Figure was adapted from Hill et al. (117) (See Appendix 4). 
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1.3.2.4 ACPA and the pathogenesis of RA 
Studies in human RA and in experimental models of this disease provided 
evidence that the immune responses to citrullinated protein/peptides targets are involved 
in pathogenesis of RA. (98, 101-102, 124-127).  ACPA can be detected in humans years 
before clinical RA onset (128-130), and their titres increase until disease initiation.  
Radiological and histological analyses show that the presence of high titres of ACPA 
predicts more erosive and severe disease (131).  Petkova et al. demonstrated  that passive 
transfer of human ACPA positive serum is able to cause a transient form of arthritis in 
autoimmune susceptible, FcγRIIb deficient mice (124).  The laboratory of Dr. Ewa 
Cairns extended this observation further and directly showed that it is ACPA that cause 
disease in the same mouse strain (132). This was achieved by affinity purification of 
ACPA from the human serum using the JED peptide and injection of these human 
purified ACPA antibodies into FcγRIIb deficient mice. These mice express citrulline in 
their joints. FCγRIIb deficient mice who received ACPA developed transient arthritis but 
the mice that received IgG void of ACPA did not.  The same human ACPA did not cause 
arthritis in B6 mice unless citrullinated protein target was injected into the joint. These 
experimental findings emphasize that arthritogenicity of human ACPA is highly 
dependent on the presence of citrullinated antigen in the joint.  
Studies in experimental animal models of RA further support the notion that 
citrullination and immune responses to citrulline are important in pathogenesis of RA.  It 
was reported that concomitant injection of a monoclonal antibody targeting citrullinated 
collagen II increased severity of the Collagen Induced Arthritis (CIA) model (101, 126-
127).  Further evidence was obtained by the development of a citrullinated fibrinogen 
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induced arthritis model in this laboratory (98).  This model consists of humanized DR4 
Tg mice that express chimeric MHC class II molecule with the SE.  These mice have a 
C57BL/6 background but do not express any of their endogenous murine MHC class II 
(133).  The chimeric MHC class II includes the peptide binding region of human origin 
with the SE, however the rest of the molecule is the mouse form of the protein (Figure 
1.4).  This means that the mice APCs can present peptides to T cells in a similar manner 
as RA patients who express the SE. 
1.3.2.5 Current model for ACPA involvement in the pathogenesis of RA 
Although the exact etiology of RA is unknown, current research findings allow the 
proposal of a model for the pathogenesis of RA. This model involves at least two events.  
The first event is break in immunological tolerance.  This occurs in periphery through 
citrullination and ACPA production in genetically susceptible subjects expressing the SE.  
In such subjects, infection or injury causes inflammation and cell death.  This leads to 
PAD activation, and the subsequent citrullination of proteins generates peptides with 
novel epitopes.  If these citrullinated antigens are not cleared efficiently, possibly due to 
defects in phagocytosis or merely an overwhelming amount of cell death, citrullinated 
antigens are taken up by APCs. The citrullinated peptides derived from these antigens are 
able to bind to the SE with high affinity are presented to citrulline-specific CD4+ T cells 
and cause their activation. As a consequence, activated citrulline-specific CD4+ T cells 
will help B cells to produce IgG ACPA.  This first event is believed to demarcate pre-
clinical RA which with time can develop into RA if the second event takes place.   
The second event takes place in the joint and can be triggered by infection or physical  
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Figure 1.4  DR4 Tg mouse MHC class II peptide presentation. Citrullinated peptide is 
bound to the DR4 Tg mouse, chimeric MHC class II molecule with the SE.  The peptide 
in the context of MHC molecule is recognized by a CD4+ T cell receptor.  
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injury causing acute inflammation resulting in the production of citrullinated protein 
targets.  Again, with insufficient clearance of these citrullinated protein targets, ACPA 
can form antigen:antibody complexes which activate complement cascade.  This cycle of 
ACPA causing inflammation which leads to increased citrullination of proteins in the 
joint can then exacerbate and perpetuate inflammatory disease leading to sustained, 
chronic inflammation and clinical RA (Figure 1.5). The strong association of RA with the 
SE, the presence of IgG and IgA ACPA isotypes, and the large number of CD4+ T cells 
in the RA joint, support the notion that citrullination and citrulline-specific immune 
responses play an important role in arthritogenesis 
1.3.3 Anti-Homocitrullined Protein/Peptide Antibodies (AHPA) 
Anti-Homocitrullinated Protein/Peptide Antibodies (AHPA) are antibodies which 
bind to proteins or peptides that have undergone the post-translational modification 
known as homocitrullination (described in 1.3.3.1).  It has been demonstrated that RA 
patients can generate AHPA and homocitrullinated protein targets of these antibodies can 
be found in the RA synovium (86, 134), however, the sensitivity of these antibodies in 
RA has not been well characterized and their specificity to this disease is unknown.   
1.3.3.1 Homocitrullination 
The carbamylation of lysine’s side-chain, a process known as homocitrullination, 
generates the amino acid homocitrulline (135).  Homocitrulline is very similar to 
citrulline, both structurally and chemically as it has the exact same functional, ureido 
group (Figure 1.2B).  The only major structural difference of the two amino acids is that 
the side-chain of homocitrulline is extended by one carbon making its total bond length  
21 
 
 
  
22 
 
 
approximately 1.56 Å longer from the backbone α-carbon to the terminal, ureido carbon 
after hydrochloride crystallization (136).   
Unlike citrullination which is catalyzed enzymatically, homocitrullination is a 
chemical modification.  Although the exact reaction mechanism seems unclear, 
homocitrullination can occur ubiquitously as long as the reactive metabolite, 
cyanate/cyanic acid, is present.  Cyanate is generated in the body by at least two sources.  
The first of which is the spontaneous degradation of urea.  Urea is ubiquitous in the body 
and always in equilibrium with cyanate.  It is estimated that at physiological conditions, 
approximately 0.8% of the molar concentration of urea is in the cyanate form (137).  
Therefore, wherever there is urea, there is cyanate and the potential for 
homocitrullination.  The second source is production by the enzyme MyeloPerOxidase 
(MPO).  MPO is found primarily in neutrophil granules and is active at sites of 
inflammation.  When the enzyme encounters thiocyante (its preferred substrate) it 
catalyzes conversion to cyanate (138).  Thus, while increased levels of urea promote 
carbamylation systemically, MPO provides a mechanism for localized increase in cyanate 
levels at the sites of inflammation. 
Early research into carbamylation focused on the modification of serum proteins 
during renal failure and the interference of carbamylation with protein identification and 
analysis.  Like other protein modifications, carbamylation can lead to altered isoelectric 
points, protein structure, and enzymatic function.  It has even been shown that 
carbamylation can cause altered hormone activity, and interfere with protein synthesis 
and insulin uptake (139).  Carbamylation was previously implicated in the formation of 
cataracts and more recently, it was reported to be involved in the molecular pathogenesis  
23 
 
 
of atherosclerosis (138, 140).  The chemical modification, carbamylation can clearly have 
a wide variety of effects on biological molecules and processes. 
1.3.3.2 Homocitrullination in RA 
Homocitrullination was originally introduced into RA research through the 
observation that the AMC reagent commonly used to detect citrulline also stained 
homocitrulline (141).    This suggested that some of the previous in situ identification of 
citrulline in arthritic joint tissue may have been homocitrulline.  The same study also 
demonstrated that homocitrulline could be immunogenic.  They reported that rabbits 
immunized with homocitrullinated protein could produce AHPA and also suggested that 
in some rabbits these antibodies could bind citrullinated targets as well.  Additional 
evidence for homocitrulline immunogenicity was provided by Mydel et al. who further 
demonstrated an arthritogenic role for anti-homocitrulline immune responses.  They 
reported that immunization of some strains of mice with homocitrullinated peptide can 
cause erosive arthritis (86).  Their study was also the first to report that human RA 
patients can have AHPA and homocitrulline in the joints and circulation.  They found 
that levels of AHPA and circulating homocitrulline were greater in patients with erosive 
RA.  Their observations were recently confirmed by Shi et al who also reported that 
AHPA correlated with joint damage but additionally found AHPA in ACPA-negative RA 
patients (134).  This latter study by Shi and colleagues demonstrated that human RA 
patients had antibodies to carbamylated fibrinogen and demonstrated that these antibodies 
do not recognize citrullinated fibrinogen.  Neither Mydel or Shi’s study addressed the 
question of whether anti-homocitrulline antibodies are specific for human RA by testing 
AHPA in other inflammatory rheumatic conditions. 
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1.4 Rationale and hypothesis 
Numerous studies have shown that citrullination is important in the pathogenesis 
of RA.  The modification can alter protein structure to generate neo-epitopes that trigger 
autoimmune responses and generation of ACPA which target various citrullinated human 
proteins that are found in the RA joint.  This laboratory has previously shown that the 
RA-associated SE plays an important role in this process. It can bind citrullinated 
peptides with high affinity leading to the activation of auto-reactive T cells and 
subsequent production of ACPA which are found specifically in RA patients and play a 
role in arthritogenesis.   
Homocitrulline is related to citrulline both structurally and chemically.  Since 
homocitrullination can alter protein structure, it will also be able to generate neo-epitopes 
on human proteins that are recognized by the immune system.   
The hypothesis of this study is that homocitrullination is involved in RA.  More 
specifically, it is hypothesized that homocitrulline will be able to bind to the SE, like 
citrulline can. This will result in activation of homocitrulline specific T cells and AHPA 
production. The APHA will be found in RA patients specifically. Some ACPA will be 
able to bind both citrullinated and homocitrullinated antigens. 
1.4.1 Specific objectives 
i) Homocitrullinate human fibrinogen and analyze sites of potential modification to 
identify potential autoantibody targets. 
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ii) Screen sera from RA, psoriatic arthritis and SLE patients as well as normal individuals 
for Anti-Homocitrullinated Fibrinogen Antibodies (AHFA) to investigate if these AHPA 
are specific to RA among inflammatory, rheumatic disease. 
iii) Investigate the role of the SE in homocitrulline immunogenicity using molecular 
modelling and DR4 Tg mice expressing the SE.  Since the SE is strongly linked to RA 
and it restricts the production of ACPA, the SE may also affect anti-homocitrulline 
immune responses and AHPA production in RA patients. 
iv) Affinity purify ACPA with citrullinated peptide (JED) and test for “cross-reactivity” 
to homocitrullinated antigen.  Since ACPA have previously been shown to be pathogenic, 
the existence of cross-reactive antibodies which bind both citrullinated and 
homocitrullinated antigens could add additional complexity to the current two-hit model. 
Citrulline/homocitrulline cross-reactivity may introduce novel mechanisms for break in 
immunological tolerance and/or the generation of autoantibody targets in the joint. 
 The studies presented in this thesis are significant because immune responses to 
homocitrulline may be involved in the pathogenesis of RA.  A better understanding of the 
mechanisms underlying arthritogenesis will aid the development of antigen-specific 
therapeutic treatments and improved patient care. 
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2.1 Introduction 
In autoimmune disease, the post-translational modification of native proteins can 
generate novel targets which provoke the immune system. The conversion of 
protein/peptide arginine to citrulline in Rheumatoid Arthritis (RA) is one example of this.  
In individuals with the Shared Epitope (SE), arginine to citrulline conversion increases 
peptide binding affinity to MHC class II molecules, specifically in the P4 binding pocket 
(1). The subsequent T cell immune response to citrullinated peptides, and production of 
Anti-Citrullinated Protein/Peptide Antibodies (ACPA), is highly specific for RA (>95%) 
(2).  ACPA can occur years before onset (3-5) and some studies show that their presence 
correlates with disease severity (6).  Taken together, it is not surprising that these 
citrulline-targeting antibodies have been implicated in RA pathogenesis and there is 
recent evidence to support such claims. More specifically, in some murine models: 
monoclonal antibodies targeting citrullinated collagen II can exacerbate disease in 
collagen-induced arthritis (7-9), immunization with citrullinated fibrinogen can cause 
arthritis (10), and passive transfer of human RA serum (11) or IgG ACPA can cause 
transient arthritis (12).  
A recent study showed that Anti-Modified Citrulline (AMC) antibodies, which 
have been utilized to detect citrullinated proteins/peptides in situ, can also detect the 
amino acid homocitrulline (13).  Homocitrulline is structurally and chemically very 
similar to citrulline, with both having the same functional group (ureido group); however, 
homocitrulline’s side-chain is larger due to the presence of an additional carbon atom.  
Whereas citrulline is generated by the enzymatic modification of arginine residues by 
Peptidyl Arginine Deiminase (PAD) (14), homocitrulline is generated chemically by the 
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reaction of cyanate with an amine group of lysine residues (carbamylation) (15).  The 
cyanate required for carbamylation can be found in the body from at least two sources: 
the spontaneous dissociation of urea (16), and production by the enzyme 
Myeloperoxidase (MPO) which is active at sites of inflammation.  Enzymatic production 
of cyanate during inflammation can be enhanced by environmental influence through the 
increase of serum thiocyanate - MPO’s preferred substrate, which is converted to cyanate 
(16-19).  One such environmental factor is smoking, a well known risk factor for RA 
(20). 
The initial evidence implicating a role for homocitrulline in RA was provided by 
Mydel et al.  They showed that in some mice, immunization with homocitrullinated 
filaggrin peptides triggered an immune response that led to erosive arthritis and some RA 
patients had antibodies which targeted this homocitrullinated peptide (21).  More 
recently, Shi et al. also reported that RA patients have antibodies which bind to 
homocitrullinated proteins (AHPA), but additionally observed that AHPA predicted joint 
damage (22).  Sera from patients with other inflammatory rheumatic diseases were not 
tested. Therefore, it is unclear whether this response is specific to RA. 
Since citrullination and ACPA production was first identified and linked to RA, 
there has been an interest in mapping protein sites which can be modified and targeted by 
antibodies.  Citrullinated fibrinogen (or citrullinated peptides derived from fibrinogen) is 
a frequently identified target of ACPA (23)  and is often found in the joints of RA 
patients (24-25).  We therefore investigated whether homocitrullinated human fibrinogen 
is a target of IgG antibodies exclusively in RA, and whether some ACPA are able to bind 
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homocitrullinated proteins/peptides as well. We also examined whether the SE can be 
involved with homocitrulline immunogenicity. 
2.2 Materials and methods 
2.2.1 Patients 
Sera were obtained from 84 RA patients (Table 2.1) attending St. Joseph’s Health 
Centre Rheumatology Clinic (London, Ontario), as well as 37 Psoriatic Arthritis (PsA) 
patients, 37 Systemic Lupus Erythematosus (SLE) patients and 27 normal individuals.  
All RA patients fulfilled the American College of Rheumatology classification criteria 
for RA (26).  This research study was approved by the Human Ethics Committee of 
Western University, London, ON, Canada. 
2.2.2 Mice 
DR4-IE Transgenic (Tg), murine MHC class II-deficient mice (27) were bred in a 
specific pathogen free animal facility at Western University.  The corresponding Wild-
Type (WT) background strain, C57BL/6 mice (referred to as B6 mice), were purchased 
from The Jackson Laboratory (Maine, USA).  8-12 week old mice were used for these 
experiments and housed in the Animal Care and Veterinary Services Barrier Facility at 
Western University under specific pathogen free conditions for the duration of study.  All 
procedures were approved by the Animal Care and Use Committee. 
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Table 2.1  RA Patient Demographics. 
 Mean SD 
Age (Years)  59.11 13.6 
Disease Duration (Years) 9.4 10.14 
Health Assessment Questionnaire 0.96 0.75 
Swollen Joint Count 4.34 6.06 
Gender (25% Male: 75% Female) - - 
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2.2.3 Mouse immunization 
Mice were immunized subcutaneously in each inner flank with 50µg of antigen 
(or equivalent volume of Phosphate Buffered Saline (PBS)) emulsified with Complete 
Freund’s Adjuvant (CFA) in 1v:1v ratio for a total of 100µg of protein in 100µL as 
previously described (10).  CFA was prepared by supplementing Incomplete Freund’s 
Adjuvant (IFA) (Sigma-Aldrich Co, Canada) with 4 mg/ml of dessicated Mycobacterium 
tuberculosis HA37 (Becton, Dickinson and Co., Franklin Lakes, NJ, USA).  On day 21 
post-primary immunization mice received booster immunizations in an identical manner 
with IFA instead of CFA.  Mice were sacrificed at various time points post-immunization 
to study their immune response to antigens.  Spleens were harvested, blood was obtained 
by cardiac puncture and sera were collected after blood centrifugation for antibody 
analyses. 
2.2.4 Antigens 
The following proteins and peptides were used for immunization of mice, ACPA 
affinity purification, and/or antibody assays: 
1. Human Fibrinogen (CalBiochemTM) – Fibrinogen was used in either its 
unmodified, citrullinated or homocitrullinated form (see “modifications of 
fibrinogen” below). 
2. JED - A proprietary synthetic citrullinated peptide developed by us and 
previously described (28-29).  
Sequence: SCCitCitYCitGCitCitSCitCitSCitCitRCS, cyclized with a C-C bond. 
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3. Homocitrullinated JED - Homocitrullinated JED was identical to JED with the 
exception that all citrulline residues were replaced with homocitrulline.   
JED and homocitrullinated JED were synthesized at the Advanced Protein 
Technology Centre, Peptide Synthesis Facility at Sick Kids Hospital in Toronto, Ontario.  
Proteins and peptides were dissolved in sterile, distilled water or sterile PBS with the 
exception that homocitrullinated JED was dissolved in 7.5% concentrated HCl in sterile 
distilled water. 
2.2.5 Modifications of fibrinogen 
2.2.5.1 Fibrinogen citrullination 
Human fibrinogen was citrullinated as previously described (23).  Briefly, 
fibrinogen was incubated with 7U/mg rabbit skeletal PAD II (Sigma) for 3 h at 52°C in 
0.1 M Tris-HCL (pH7.4), 10 mM CaCl2 buffer.  PAD was removed by spinning 15 mL 
volumes of the reaction mixture and PBS through a 100K Macrosept column (Pall 
Corporation) 3 times.  Gel electrophoresis and mass spectrometry were preformed to 
confirm citrullination (see 2.2.5.3 below). 
2.2.5.2 Fibrinogen homocitrullination 
Human fibrinogen was homocitrullinated using treatment with 0.1 M KOCN in 
0.15 M sodium phosphate buffer and incubation at 37°C for 24 h.  10 mg of fibrinogen 
was homocitrullinated in a 5 mL reaction.  Excess KOCN was removed by spinning 15 
mL volumes of the reaction mixture and PBS through a 100K Macrosept column (Pall 
Corporation) 3 times.  Gel electrophoresis and mass spectrometry were preformed to 
confirm homocitrullination (see 2.2.5.3 below). 
2.2.5.3 Fibrinogen digestion and analysis 
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The remaining concentrated, modified human fibrinogen was used alongside 
unmodified fibrinogen in 12% SDS gel electrophoresis with Coomassie blue staining.  
From the gel, protein bands representing each chain of fibrinogen were isolated using an 
Ettan Spot Picker (GE Healthcare) and submitted to Western University Functional 
Proteomics Facility (London, Ontario) for digestion.  In-gel digestion was performed 
using a MassPREP automated digester station (PerkinElmer).  Gel pieces were 
Coomassie destained using 50 mM ammonium bicarbonate and 50% acetonitrile, which 
was followed by protein reduction using 10 mM dithiotreitol (DTT), and alkylation using 
55 mM iodoacetamide (IAA).  Samples were then digested with approximately 5 ng/µL 
of sequencing grade porcine trypsin (Promega Corporation).  After digestion, peptides 
were extracted using a solution of 1% formic acid and 2% acetonitrile and lyophilized.  
For mass spectrometry analysis, samples were reconstituted in 20 µL of 0.1% formic 
acid in water and 10 µL of each sample was analyzed using a 70 min LC-MSMS method.  
Separation using LC (5-60% ACN 0.1% FA over 40 min gradient) was performed on a 
Waters nano Acquity UPLC, (Ultra Performance Liquid Chromatography) with a 75 µm 
x 250 mm, 1.7 µm, C18, reverse phase column (Waters).  Ions were detected in ES 
(Electrospray) MS+ve ion mode using DDA (Data Dependent Acquisition), (Q-ToF 
Global; Waters).  Mass spectrometry was analyzed using MASCOT server with the 
NCBInr 101910 database (Homo sapiens taxonomy specified) and the following 
acceptable modifications: Carbamidomethyl (C), Oxidation (M), Phospho (ST), Phospho 
(Y), and either Carbamyl (K) or Citrullination (R). 
2.2.6 Molecular modelling 
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The available, published X-ray crystallographic structures of peptides bound to the 
SE positive MHC class II DR0401 molecule (30-32) were initially analyzed in pairs.  For 
each pair of structures, the back bone atoms of the of the MHC class II DR0401  -chain 
that contain the SE sequence were superimposed using the “Magic Fit” function of Swiss 
PDB Viewer.  In the same program, variation in peptide orientation was measured by the 
average distance between backbone atoms, measured as a Root Mean Squared (RMS).   
The crystal structure of collagen II peptide 261-273 bound to MHC class II DR0401 
SE (PDB code 2SEB) (30) was used for further molecular modelling which was done by 
substituting the aspartic acid binding at the P4 position to various rotomers of lysine or 
arginine without changing the backbone atom orientation.   A custom written file was 
used in PyMOL to modify the lysine/arginine residues further to 
homocitrulline/citrulline.  The modified structures were then analyzed in 
SwissPDBViewer for steric clashes.   
Modified fibrinogen (citrullinated or homocitrullinated) peptide binding to the SE 
was predicted using a program written by Hammer et al. (33) as previously described by 
us for the prediction of citrullinated peptides binding to the SE (1).  This relied on the 
assumption that homocitrulline bound similarily to the SE as citrulline.  Briefly, lysine 
residues (potential homocitrullination sites) were changed to glutamine because its side-
chain functional group is most similar to homocitrulline (and citrulline).  The program 
then compared each 9 residue long, continuous peptide to the known consensus binding 
motif for the MHC class II DR0401 molecule and assigned a score.  All peptides with a 
score of 2.0 or higher were considered SE binders. 
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2.2.7 ACPA purification 
ACPA was affinity purified using Hi-trap NHS-Activated (GE) column 
chromatography as per manufacturer’s instructions and as previously described (28).  
Briefly, 3 mg of citrullinated JED peptide was linked to a 1 mL column.  Five mL of 
serum from each patient was diluted separately with 20 mL of binding buffer (20 mM 
sodium phosphate buffer, pH 7.4) and run through the column. Anti-JED was eluted from 
the column using 10 mM sodium phosphate, 2.5 M MgCL2 buffer and antibodies were 
transferred to PBS using a desalting column (GE) as per manufacturer’s instructions.  The 
third mL eluted from the desalting column consistently had the most IgG and was, 
therefore used for analyses. 
2.2.8 Antibody assays 
Human sera (and/or purified ACPA) were tested for the presence of antibodies that 
bound to JED, homocitrullinated JED, citrullinated fibrinogen, and homocitrullinated 
fibrinogen using Enzyme-Linked ImmunoSorbant Assay (ELISA) with 1:100 dilution 
except if high titres required further serial dilution for accurate quantification.  Mouse 
sera were tested for anti-homocitrullinated fibrinogen antibodies at 1:30000 and for anti-
JED antibodies at 1:100. 
All ELISAs were performed at room temperature as previously described (10, 23).  In 
brief, MaxiSorp Nunc 96-well plates (Thermo Scientific Inc.) were coated with 1 µg of 
protein or peptide/well in carbonate coating buffer (10 µg antigen/mL) overnight at 4°C.  
Plates were then washed with PBS, 0.05% Tween (PBST) and blocked with PBS, 0.1% 
BSA.  After washing, human or mouse serum samples diluted in PBST 0.1% BSA were 
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incubated in duplicate on the plate for 30 minutes before being washed away with PBST.  
Biotin-conjugated goat anti–mouse IgG secondary antibodies (Sigma) or biotin-
conjugated goat anti–human IgG secondary antibodies (Sigma) were diluted 1:10,000 in 
PBST, 0.1% BSA containing streptavidin/horseradish peroxidase diluted 1:4,000 (Sigma-
Aldrich) and incubated in the wells for 30 min before being washed with PBST.  100 µL 
of TetraMethyl Benadine substrate (Sigma) was incubated in each well for 10 minutes 
before the reaction was stopped with 50 µL of 2M H2SO4.  To quantify antibody 
concentrations in sera, Optical Density (OD) at 450 nm was read using a microplate 
reader (BIORAD).  Antibody reactivity to BSA (Sigma) was subtracted from each 
duplicate sample.   
Antibody inhibition was tested using the ELISA described above with the exception 
that various amounts of soluble antigen in PBST, 0.1% BSA were pre-incubated with 
diluted serum for one hour at room temperature prior to incubation on ELISA plate. 
Antibodies to homocitrullinated fibrinogen and the synthetic peptides JED and 
homocitrullinated JED were quantified in Arbitrary Units/mL (AU/mL) by comparison to 
a reference serum sample for each antigen.  Briefly, the 1:100 dilution of reference serum 
was assigned a concentration of 250 AU/mL and serial dilutions were used to produce a 
standard curve (Absorbance vs. Concentration).  Absorbance of unknown normal and 
patient sera were then compared to the standard to determine concentration.  The cut-off 
value for positive anti-JED was 3.5 AU/mL, for anti-homocitrullinated JED was 18.5 
AU/mL and for anti-homocitrullinated fibrinogen was 3.6 AU/mL.  Cut-off values were 
determined using the mean of normal sera reactivity + 2 standard deviations. 
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Anti-CCP2 antibodies were detected in human serum using a commercially available 
ELISA kit (Euroimmun AG).   
Total IgG was measured in mg/mL using a commercially available ELISA kit 
(Cedarlane). 
2.2.9 Proliferation assay 
Spleens were harvested from mice sacrificed at different times post-immunization 
and their splenocyes were suspended in complete RPMI (1% Glutamax (Gibco), 1% 
penicillin/streptomycin (Gibco), 1% sodium pyruvate (Gibco), 1% non-essential amino 
acids (Gibco), 0.25% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
(Gibco)) supplemented with 5% Fetal Bovine Serum (FBS) (Gibco).  400,000 
splenocytes per well were cultured in 96-well U-bottom plates (BD) with 50 µg/mL 
antigen for 72 hours at 37°C, 5% CO2.  1 µCi of [
3
H]thymidine (ICN Biomedicals, Irvine, 
CA, USA) was added to each well 18 hours prior to culture termination.  Cells were 
harvested using a Tomtec Harvester 96 and immersed in scintillation fluid before 
radioactive counts were read in counts per minute (cpm) using a Wallac 1450 microbeta 
liquid scintillation counter.  Spleen cell proliferation experiments were conducted in 
quadruplicate, and the results are presented as the mean stimulation index (cpm of 
experimental sample/cpm of control sample) ± the SEM. 
2.2.10 Statistical analysis  
Mann-Whitney U test was used to compare groups in Graphpad Prism V5 and a p 
value of <0.05 was considered significant. 
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2.3 Results 
2.3.1 Occurrence of anti-homocitrullined fibrinogen antibodies in RA, patients 
with other inflammatory rheumatic diseases, and healthy individuals 
We used in vitro carbamylated fibrinogen as a homocitrullinated antigen to determine 
the presence of Anti-Homocitrullinated Fibrinogen Antibodies (AHFA) in sera from RA 
(n=84, Table 2.1), SLE (n=37), and psoriatic arthritis (PsA) (n=37) patients and normal 
individuals (n=27) (Figure 2.1A).  Serum antibody reactivity was significantly increased 
in RA only (p<0.05).  Only 5% of SLE patients and 3% of PsA patients tested weakly 
positive for anti-homocitrullinated fibrinogen antibodies (AHFA). In our RA cohort that 
was 89% anti-CCP2 positive, reactivity to homocitrullinated fibrinogen was detected in 
49% of patients. 69% of the RA patients also had Anti-Citrullinated Fibrinogen 
Antibodies (ACFA).  Although AHFA were not found in any of the 10 RA patients 
without anti-CCP2, 6% of the RA patients had AHFA but did not have antibodies to the 
citrullinated form of fibrinogen (Table 2.2).   
To confirm that the observed antibodies to homocitrullinated fibrinogen involved 
homocitrulline containing epitopes, serum from three different RA patients with AHFA 
(two of which were also Anti-Citrullinated Fibrinogen (ACFA) positive) were inhibited 
with either soluble homocitrullinated fibrinogen or soluble unmodified fibrinogen  
(Figure 2.1B).  In all three cases, there was an increase of inhibition from 25-38% with 
unmodified fibrinogen up to 71-89% with the equivalent concentrations of 
homocitrullinated fibrinogen.  This suggests that a large portion of the AHFA response 
(approximately 67%) is homocitrulline specific. 
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Table 2.2  Summary of human serology findings. 
 RA (n=84) Normal (n=27) SLE (n=37) PsA (n=37) 
anti-CCP2 + 74 (88) 0 (0) 2 (5) 1 (3) 
AHFA +  41 (49) 0 (0) 2 (5) 1 (3) 
ACFA + 58 (69) 0 (0) - - 
AHFA +, ACFA + 36 (43) 0 (0) - - 
AHFA -, ACFA + 22 (26) 0 (0) - - 
AHFA +, ACFA - 5 (6) 0 (0) - - 
Values shown represent: number of individuals who tested positive (percentage) 
SLE = Systemic Lupus Erythematosus 
PsA = Psoriatic Arthritis 
AHFA = Anti-Homocitrullinated Fibrinogen Antibodies; 
ACFA = Anti-Citrullinated Fibrinogen Antibodes. 
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Figure 2.1  Antibodies that bind homocitrullinated fibrinogen are specific to RA. A) 
ELISA detecting serum antibodies that bind to homocitrullinated fibrinogen in normal 
subjects (n=27) and RA (n=84), SLE (n=37), and Psoriatic Arthritis (n=37) patients. B) 
ELISA demonstrating inhibition of anti-homocitrullinated fibrinogen antibodies from RA 
patients (N=3) with various quantities of either soluble unmodified fibrinogen or soluble 
homocitrullinated fibrinogen. 
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2.3.2 Affinity purified human ACPA can bind homocitrulline 
We next investigated whether anti-citrulline antibodies were also able to bind 
homocitrullinated protein and peptide.  ACPA was affinity purified from the sera of five 
different RA patients using a the citrullinated JED peptide and antibody reactivity with 
CCP2, citrullinated JED, citrullinated fibrinogen, homocitrullinated JED, and 
homocitrullinated fibrinogen was measured in AU/mg of IgG and compared to serum 
values to determine enrichment (Table 2.3).  Enrichment (purified concentration/serum 
concentration) of JED reactivity was seen in all five purifications with an average 172 
times increase in concentration (AU/mg of IgG).  Co-enrichment of anti-CCP2 and anti- 
citrullinated fibrinogen antibody reactivity was also observed with an average 94 times 
and 182 times increase in concentration (RU/mg of IgG), respectively whereas a 
reduction of antibody reactivity to all citrullinated antigens was observed in the IgG 
flowthrough remaing after purification.  This provides evidence that our procedure 
successfully affinity purified ACPA. Interestingly, purification of ACPA from all five 
RA patients also strongly enriched AHPA (average 150 times increase in anti-
homocitrullinated JED concentration) while in the remaining flowthrough IgG that did 
not bind the citrullinated JED column, concentration of anti-homocitrullinated JED was 
consistently reduced.  All three patients with strong serum anti-homocitrullinated 
fibrinogen antibodies also showed enrichment (average of 76 times) after citrullinated 
JED purification, however this cross-reactivity was not complete as some remaining 
flowthrough IgG fractions were also enriched for anti-homocitrullinated fibrinogen 
antibodies.  This demonstrates that at least some antibodies that bind citrullinated peptide 
(ACPA) are also able to bind to homocitrullinated proteins and peptides as well. 
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2.3.3 Human fibrinogen is extensively accessible to both homocitrullination 
and citrullination 
Since lysine can be found in different regions of proteins than arginine, we sought 
to investigate which sites of human fibrinogen could be homocitrullinated and potentially 
serve as a target of AHPA.  Fibrinogen’s primary structure includes 103 lysines as 
opposed to 80 arginines.  Of the 100 lysines that were successfully analyzed by mass 
spectrometry, 89 of them (89%) were capable of modification to homocitrulline. Similar 
analysis of citrullination showed that 55 of the 71 (78%) of arginines which were 
analyzed were able to be modified in vitro (summarized in Table 2.4).  Neither citrulline 
nor homocitrulline were detected with mass spectrometry in our sample of unmodified 
human fibrinogen (Representative mass spectra of homocitrullination and citrullination in 
Appendix 1 and Appendix 2, respectively; complete homocitrullination and citrullination 
sequence analysis in Appendix 3). 
Using the modelling program developed by Hammer et al. (33) as previously 
described (1), with the assumption that homocitrulline could bind to MHC Class II 
molecules like citrulline, 35 peptides were predicted to bind to the SE after 
homocitrullination.  Of these peptides, five could be citrullinated by PAD in vitro as well.  
Therefore, there are potentially antigenic regions which are subject to both citrullination 
and homocitrullination in close proximity. 
2.3.4 The Shared Epitope can accommodate homocitrulline  
To investigate whether the SE can be involved in the immune response to homocitrulline 
we attempted to model this interaction.  To date, three different peptides bound to the  
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Table 2.4  Summary of mass spectrometry on modified fibrinogen. 
Modification α  γ Total 
Homocitrullination      
Lysines  38 31 34 103 
Lysines analyzed by mass spectrometry 37 31 32 100 
Homocitrullinated  33 29 27 89 
Predicted to bind the SE
*
 12 13 10 35 
Predicted binders also citrullinated  2 3 0 5 
Citrullination      
Arginines  42 27 11 80 
Arginines analyzed by mass spectrometry 35 27 9 71 
Citrullinated  29 19 7 55 
*Predicted using the algorithm generated by Hammer et al. (33) 
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MHC II DR0401 molecule have had structural data obtained through X-ray 
crystallography but none contained citrulline or homocitrulline (Table 2.5).  The first is a 
peptide from human collagen II, the second is a peptide derived from the influenza HA 
antigen, and the third is a peptide from human Myelin Basic Protein (MBP). To help 
validate our mutational modelling strategy, we first investigated changes in peptide 
backbone orientation between existing structures.  This helps to ensure that side-chain 
conformation (not backbone variation) was of primary importance in determining 
whether the SE can accommodate homocitrulline.  When the backbone atoms of the HLA 
DR4 -chain that contain the SE sequence are superimposed using the “Magic Fit” 
function of Swiss PDB Viewer, the backbone atoms of the 9 peptide amino acid residues 
binding the P1-P9 pockets (see Table 2.5) differed in structural orientation by an average 
difference of 0.71 Å, 1.18 Å, and 1.02 Å in structures 1 vs 2, 1 vs 3, and 2 vs 3, 
respectively (measured as a Root Mean Squared (RMS)).  Similar analysis of only the 
P1-4 residues reveals lower overall variation with orientation differences of 0.72 Å, 0.66 
Å, and 0.56 Å, respectively after superimposition of the same structure pairs.  Therefore, 
there was little variation in peptide backbone orientation of the 9 amino acid residues 
which were most important for peptide binding.  Additionally, the first four amino acids, 
(including the P4 position that interacts with the SE) had orientations which were most 
conserved, as the majority of differences in conformation were seen in the C-terminal 
portion of the peptides (Figure 2.2). 
The P4 pocket that is known to be capable of accommodating citrulline is 
occupied by aspartic acid, glutamine and glutamic acid in structures 1-3, respectively.  
Separate files were generated that are capable of altering these residues to either citrulline  
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Table 2.5  Peptide structures used for molecular modelling.  Summary of the peptides 
for which there are X-ray crystallographic structural data of binding to the SE.  The 9 
amino acid residues primarily involved in HLA binding specificity are underlined and the 
SE restricted amino acid which binds the “Position 4” (P4) pocket is bolded. 
# PDB 
Code 
Source Protein Location Sequence Structure 
Resolution 
1 2SEB Human Collagen II 1168-1179 AYMRADAAAGGA 2.5 Å 
2 1J8H Influenza HA Antigen 306-318 PKYVKQNTLKLAT 2.4 Å 
3 3O6F Human Myelin Basic 
Protein 
 FSWGAEGQRPGFGSGG 2.8 Å 
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Figure 2.2 Pair-wise superimpositions of the existing structures of peptides bound to 
the SE. The three existing X-ray crystallographic structures of SE positive human MHC 
class II (DR0401) bound to different peptides superimposed in pairs.  Peptide 1 is shown 
in red (MHC orange), Peptide 2 in green (MHC yellow) and Peptide 3 is shown in blue 
(MHC purple).  After fitting the structured backbone atoms of the MHC class II -chain, 
the differences in peptide orientations can be seen.  The SE restricted P4 amino acid, 
including its side-chain, is shown in black and the peptide N-terminal is positioned at the 
lower right of each image.    
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or homocitrulline in PyMOL.  Following this success, topology files were written so that 
the modified amino acids could be recognized and analyzed by the Swiss PDB Viewer 
program.  Since collagen II is a well documented target of autoantibodies in RA, we used 
the 2SEB structure for further analysis. 
Even with the additional files that were written, the modelling programs had an 
inadequate amount of data to allow manipulation of citrulline and homocitrulline side-
chain torsion angles.  Therefore, some clashes occurred after modification to either 
citrulline or homocitrulline and could not be alleviated.  As an alternative approach, the 
P4 aspartic acid residue was changed to existing conformational rotomers of arginine or 
lysine, chosen manually on the basis of available space for modification.  The P4 amino 
acid was then modified to citrulline or homocitrulline without changing the backbone 
atom position.  This method utilizing 2SEB generated structures with homocitrulline and 
citrulline orientations that fit into the SE binding pocket SE without steric hindrance 
(Figure 2.3).  Therefore, it is likely that the SE can accommodate homocitrulline. 
2.3.5 The SE does not restrict the immune response to homocitrullinated 
fibrinogen 
To investigate whether homocitrullination can cause the proliferation of immune 
cells and whether the SE restricts this process, we performed proliferation assays in 
which splenocytes from mice immunized with either unmodified or homocitrullinated 
human fibrinogen, or PBS alone were re-exposed in vitro to either unmodified or 
homocitrullinated human fibrinogen (Figure 2.4).  Both DR4 Tg and B6 mice immunized 
with either unmodified or homocitrullinated fibrinogen had a proliferative response  
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Figure 2.3  The SE can accommodate homocitrulline.  Molecular modelling images of 
collagen peptide (261-273) binding MHC class II DR0401 (PDB structure 2SEB) after 
citrullination (left) or homocitrullination (right) of the P4 position.  Collagen peptide is 
shown in green with homocitrulline colored red.  Homocitrulline is shown in the P4 
binding pocket (blue) with the SE colored orange.  The MHC class II DR0401 SE 
accommodates homocitrulline without steric hindrance.  
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compared to mice immunized with PBS alone.  In DR4 Tg mice 10 days post-
immunization, there was a significantly greater response in mice immunized with and re- 
exposed to homocitrullinated fibrinogen compared to mice immunized with and re- 
exposed to unmodified fibrinogen.  Also, the DR4 Tg mice 10 days post-immunization 
with unmodified fibrinogen had a significantly higher response to homocitrullinated 
fibrinogen compared to re-exposure to unmodified fibrinogen, however, after 
immunization with homocitrullinated fibrinogen, no groups of mice had a significantly 
greater response upon re-exposure to the homocitrullinated form of fibrinogen compared 
to the unmodified form.  Therefore, we were unable to detect any homocitrulline specific 
T cell response in DR4 Tg or B6 mice.  Although not statistically significant, each 
individual mouse (both DR4 Tg and B6) did have an increased proliferative response to 
homocitrullinated fibrinogen compared to unmodified fibrinogen after immunization with 
either form of the protein.  Since B6 mice responded to homocitrullinated fibrinogen, the 
immune response to the protein modification appears to not be SE restricted in mice.  
2.3.6 Anti-homocitrulline antibody responses in DR4 Tg and B6 mice  
To determine if the mice immunized with homocitrullinated fibrinogen or 
unmodified fibrinogen generated antibody responses, and to study the nature of these 
responses, we tested the antibody reactivity of mouse sera to homocitrullinated fibrinogen 
and inhibited this response with either soluble unmodified or homocitrullinated 
fibrinogen.  All mice immunized with fibrinogen produced IgG anti-fibrinogen antibodies 
compared to mice immunized with PBS alone (p<0.001) (Figure 2.5A).  Subsequently, 
antibody reactivity was inhibited with both unmodified and homocitrullinated fibrinogen.  
In all mice, the homocitrullinated fibrinogen was able to inhibit all reactivity while, in  
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Figure 2.4.  Proliferative responses of splenocytes from DR4 Tg and B6 mice.   
Results from proliferation assays performed on splenocytes from DR4 Tg mice 10 (A) or 
31 days (C) post-immunization and from B6 mice 10 (B) or 31 days (D) post 
immunization after re-exposure to antigen in vitro (*= p<0.05 compared to PBS 
immunized, Fib exposed; #= p<0.05 compared to PBS immunized, HomoCitFib exposed; 
**= p<0.01).   
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Figure 2.5  Antibody responses in DR4 Tg and B6 mice.  A) ELISA detecting serum 
IgG AHFA responses in DR4 Tg and B6 immunized mice day 31 post immunization with 
PBS, unmodified fibrinogen, or homocitrullinated fibrinogen. All mice responded to 
protein vs. PBS immunization (p<0.001).  B&C) ELISA showing inhibition of AHFA 
from immunized DR4 Tg (B) and B6 (C) mice with soluble unmodified fibrinogen or 
homocitrullinated fibrinogen.  D) ELISA detecting serum anti-JED IgG ACPA in mice 
immunized with homocitrullinated fibrinogen 90 days post-immunization.  All mice 
immunized with homocitrullinated fibrinogen had higher anti-JED IgG responses than 
mice immunized with unmodified fibrinogen (p<0.01). 
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DR4 Tg and B6 immunized with homocitrullinated fibrinogen, the unmodified fibrinogen 
could only inhibit 34-53%, indicating that both mice generated a homocitrulline specific 
antibody response (Figure 2.5B and C).  Interestingly, when serum from both B6 and 
DR4 Tg mice immunized with homocitrullinated fibrinogen was tested 90 days post-
immunization for antibodies to citrullinated JED peptide, anti-JED antibodies (ACPA) 
were detected.  These were not observed with B6 and DR4 Tg mice immunized with 
unmodified fibrinogen (Figure 2.5D) or even DR4 Tg mice immunized with citrullinated 
fibrinogen (data not shown). 
2.4 Discussion 
This study showed that the protein fibrinogen is extensively accessible to 
homocitrullination and that homocitrullinated fibrinogen is a target of autoantibodies in 
RA, specifically.  We also showed that homocitrullination can generate unique neo-
epitopes on proteins and although homocitrulline is predicted to bind to the SE, the 
generation of AHPA is not restricted by the SE, unlike ACPA.  Additionally, we 
demonstrated that the targets of ACPA are not limited to citrullinated sites as previously 
thought, but at least some human ACPA is able to bind homocitrullinated protein/peptide 
as well.  Therefore, ``cross-reactive`` antibodies which can bind both citrulline and 
homocitrulline exist.  These promiscuous antibodies could have implications on current 
models of RA pathogenesis since ACPA have been shown to be arthritogenic (10-12), but 
their relevant in vivo targets have not been identified and their affinity for homocitrulline 
has not been investigated. 
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To date, there are few studies describing protein homocitrullination in 
immunology (13, 17, 21-22).    In agreement with previous work (21-22), we found that 
AHPA were produced in RA. Our study showed that a high proportion of RA patients 
had antibodies that bind homocitrullinated protein/peptide.  Initial identification of 
AHPA in humans employed carbamylated total calf serum (22), or a short peptide 
derived from filaggrin (21).  It is, however, important to study anti-homocitrulline 
responses against proteins which are found in the arthritic joint and, thus potentially 
relevant in disease pathogenesis.  The investigation by Shi et al. demonstrated that RA 
patients have AHPA that target homocitrullinated fibrinogen (22).  We also employed 
homocitrullinated fibrinogen since:  i) antibodies to citrullinated fibrinogen are highly 
specific for RA (23-25); ii) half of ACPA positive RA patients have circulating 
citrullinated fibrinogen:IgG antibody complexes (34);  iii) it is present in inflamed RA 
joints (24-25); and iv) immunization with the citrullinated form induces arthritis in DR4 
Tg mice expressing the SE (10).   
Our study showed that fibrinogen is also extensively accessible to 
homocitrullination and that there are substantially more sites for homocitrullination in 
this molecule compared to citrullination.  In agreement with Shi et al., we confirmed that 
RA patients do have antibodies which bind to homocitrullinated regions of fibrinogen 
(AHFA) (22).  Additionally, we showed that AHPA were specific to RA as AHFA were 
not found in patients with other inflammatory rheumatic conditions.  The fact that some 
RA patients in our study had antibodies targeting the homocitrullinated form of 
fibrinogen but not the citrullinated form supports the concept that homocitrullination can 
generate unique structural antigens on proteins, different from citrullination.   
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Although Shi et al. were unable to show cross-reactivity between citrullinated and 
homocitrullinated fibrinogen (22) we showed that some human ACPA can bind both 
citrulline and homocitrulline.  There are possible explanations for the differences 
observed.  Their initial study employed a single peptide in the N-terminal region of the 
fibrinogen beta-chain.  The native N-terminal region of the fibrinogen beta-chain  
includes an arginine that we confirmed can be citrullinated, but Shi et al.  also altered it 
to a lysine or homocitrulline at this position.  Studying antibodies which bind a single 
peptide, however, entails studying a very limited number of, or even a single clonal 
specificity.  Thus, this experiment demonstrated that some antibody clones are highly 
specific and are able to discriminate between citrulline and homocitrulline.  Our study, on 
the other hand, investigated the large polyclonal response of patients.  We cannot exclude 
the possibility that some affinity purified ACPA are not able to bind homocitrulline.   
Shi et al. employed the use of whole fibrinogen and studied the inhibition of anti-
homocitrullinated fibrinogen antibodies with citrullinated fibrinogen (and vice versa) 
(22).  These studies show that there is minimal inhibition by the alternatively modified 
form of fibrinogen, however, these studies do not rule out the presence of cross-reactivity 
between anti-modified fibrinogen and other protein antigens.  As we have shown, 
homocitrullination and citrullination generate distinct antigens on fibrinogen as they 
modify different amino acids which are often found in different regions of the protein.  
Additionally, antibodies do not bind single amino acids, but rather an area of protein with 
many amino acids.  The majority of cross-reactive antibodies likely occur because protein 
regions that contain homocitrulline structurally resemble an alternative protein region that 
contains citrulline.  Additionally, to cross-react, the antibodies which recognize the 
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protein structure must not exclusively discriminate between the two amino acid 
modifications (as was the case with the antibodies targeting the fibrinogen -chain 
peptide studied by Shi et al.).  Therefore, these inhibition studies conclude that there are 
no (or few) antigenic regions of homocitrullinated fibrinogen that resemble citrullinated 
fibrinogen regions (and vice versa).  Thus, there is little cross reactivity between AHFA 
and citrullinated fibrinogen or ACFA and homocitrullinated fibrinogen.  This is likely 
due to: i) a lack of structural similarity between homocitrullinated and citrullinated 
fibrinogen antigenic regions which is insufficient to facilitate cross-reactive binding; 
and/or ii) the generation of highly specific antibodies which discriminate between the 
modifications in areas that are similar.  However, just as there are sites on the 
citrullinated filaggrin protein which structurally resemble citrullinated fibrinogen (25), 
there may be modified sites on other human proteins which would cross-react with 
fibrinogen antigens and allow the inhibition of AHFA or ACFA in Shi’s experiments.  
Another important difference between our study and that of Shi et al. is the 
amount of cyanate used to homocitrullinate fibrinogen.  Since homocitrullination is a 
chemical process, not an enzymatic one, the reactant, cyanate, gets consumed in the 
process.  Therefore, if the reaction is allowed to progress to completion, the amount of 
cyanate relative to fibrinogen will determine how many lysine residues can be modified 
and, therefore which antigens will be generated.  Theoretically, if enough cyanate is 
present, all accessible lysines could be converted to homocitrulline.  Mass spectrometry 
of our homocitrullinated fibrinogen preparations showed a heterogenous population of 
fibrinogen peptides with different combinations of peptidyl lysine/homocitrulline, 
representing a wide variety of antigens.  We used 0.05 mol of KOCN/g of fibrinogen 
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while their study used twice as much.  This could have reduced their ability to detect 
cross reactive antibody specificities which rely on the presence of lysine in their antigenic 
region. 
The existence of cross-reactive antibodies was also suggested previously by 
Turunen et al.. (13) who reported that immunization of rabbits with homocitrullinated 
human albumin can trigger the generation of ACPA.  We also observed this phenomenon, 
as immunization of both DR4 Tg and B6 mice with homocitrullinated fibrinogen, but not 
citrullinated or unmodified fibrinogen, triggered ACPA production. Neither study, 
however, investigated whether the homocitrulline induced ACPA that were generated 
were still able to bind to homocitrullinated targets as well, or if the immune response was 
citrulline specific.  Interestingly, Mydel et al. reported more severe arthritis in mice 
which were immunized with homocitrullinated peptide prior to the introduction of a 
citrullinated target peptide in the joint.  All these (cross-reactivity) data suggest that, like 
citrullination, homocitrullination may be involved in the pathogenesis of RA by 
triggering the generation of autoantibodies (including ACPA) and/or by generating 
targets for antibody responses in the arthritic joint. 
Increased homocitrulline levels have been found in the serum and joints of RA 
patients by Mydel et al. (21).  Additionally, the finding that AMC stains homocitrulline 
residues as well as citrulline (13) suggests that some previous in situ identification of 
citrulline in arthritic tissue may actually have been homocitrulline.  It was also reported 
that RA patients with erosive disease, specifically, have increased circulating 
homocitrulline and higher levels of AHPA (21).  We did not investigate the presence of 
homocitrullinated protein in vivo or the correlation between disease activity/severity and 
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AHPA status.  AHPA has also been reported to be found in ACPA negative RA (22).  
This was not the case in our study, but only 10 ACPA negative RA patients were studied 
and AHPA was only detected with homocitrullinated fibrinogen.   
Mydel et al. demonstrated a role for homocitrulline sensitized T cells and MHC 
class II dependency in their mouse arthritis model (21).  We have previously shown that 
ACPA production triggered by citrullination (as opposed to homocitrullination) is 
restricted by the presence of the MHC class II SE (1) and our molecular modelling 
suggests that although homocitrulline is larger than citrulline, it can also bind to the SE.  
This computer modelling method did not consider conformational changes, or “induced 
fitting” which usually occurs through minor changes in local protein structure and result 
in improved binding.  Further investigation of homocitrulline and the SE by 
immunization of DR4 Tg and B6 mice, however, indicated that IgG AHPA production 
was not SE restricted.  We were unable to detect net homocitrulline specific T cell 
responses and the only differences detected after unmodified or homocitrullinated 
fibrinogen immunization were in DR4 Tg mice 10 days after immunization.  These mice 
seemed to have a more robust response to homocitrullinated fibrinogen however, the 
underlying cause of both differences could be the consistent inability of DR4 Tg mice to 
respond to unmodified fibrinogen early after unmodified fibrinogen immunization.  
Additional studies which utilize homocitrullinated peptide will be required to confirm 
that T cell responses were homocitrulline specific and homocitrulline bound the P4 
binding pocket, specifically.   
We showed that AHPA were indeed specific to RA as they were not found in 
normal individuals or patients with other inflammatory rheumatic conditions such as 
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Psoriatic Arthritis and SLE.  Since AHPA are not found in all individuals even though 
everyone experiences inflammation and homocitrullination, there may be factors, both 
genetic and environmental, which influence the anti-homocitrulline immune response.  
Perhaps there is a threshold of homocitrulline levels required to be immunogenic.  
Genetic variants of MPO have been investigated in studies of cancer but, to our 
knowledge, have not been studied in RA (35-36).  Since some MPO variants have 
different levels of expression, they could either enhance or restrict the production of 
cyanate (and homocitrullination potential) during inflammation.  Increased 
homocitrulline levels could also occur in people with carbamylation associated 
pathologies (17, 37-38) or specific environmental influences, since serum cyanate levels 
are increased both directly and indirectly by many different factors such as cigarette 
smoking, dietary intake, and air quality (17-18, 39).  These factors could influence the 
level of cyanate in the internal environment. 
It is unknown whether antibody responses binding to homocitrullinated and 
citrullinated targets in the joint are the sole cause and initiator of RA, however, literature 
on ACPA suggests antibodies targeting protein modifications can at least exacerbate 
disease (7, 10, 12, 40).  Our study clearly demonstrates that homocitrullination provides a 
mechanism for the generation of neo-epitopes different from those produced by 
citrullination.  We also showed that AHPA production is not restricted by the SE and 
anti-homocitrulline responses may constitute a pathway for SE-independent ACPA 
production. Furthermore, ACPA could be further classified by their binding properties to 
homocitrullinated antigens and/or by the origin of the immune response (whether 
triggered by citrullinated or homocitrullinated protein/peptide). 
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3.1 Study overview 
Post-translational modification of self proteins generates neo-epitopes that can be recognized 
by the immune system.  The identification of antibodies which target the modified amino acid, 
citrulline, and are highly specific for RA has provided new insights into disease pathogenesis (1-
3).  MHC class II genes were previously reported as the strongest genetic risk factor for RA (4) 
and have since been shown to contribute to arthritis by facilitating the immune response to 
citrullinated peptide (5).  The subsequent production of anti-citrulline antibodies (ACPA) occurs 
prior to disease onset (6-8) and there is an accumulation of evidence that ACPA are arthritogenic 
(9-11).  The recent finding that RA patients also have antibodies which target an alternative post-
translationally modified amino acid, homocitrulline (12-13), has suggested that there may be 
additional mechanisms involved in RA development and prgression. 
This research supported the hypothesis that homocitrullination and antibody responses 
targeting homocitrulline (AHPA) are also involved in RA.  It demonstrated that, as with ACPA, 
AHPA are specific for RA as well.  The protein fibrinogen, a known target of ACPA (14), was 
shown to also be extensively accessible to homocitrullination and a target of autoantibodies 
(AHFA) after such modification.  Additionally, there are substantially more sites for 
homocitrullination compared to citrullination in the fibrinogen protein.  Some RA patients had 
antibodies which targeted the homocitrullinated form of fibrinogen but not the citrullinated form 
(and vice versa).  This, combined with the previous observations that citrullinated fibrinogen 
minimally inhibits AHFA and homocitrullinated fibrinogen minimally inhibits Anti-Citrullinated 
Fibrinogen Antibodies (ACFA) (13), supports the previous notion that ACPA and AHPA can 
form distinct groups of antibodies.  Thus, homocitrullination can generate unique structural 
antigens on proteins, different from citrullination.  Although ACPA and AHPA can form distinct 
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antibody groups, this study showed that there can also be overlap between immune responses 
against the two modifications.  Specifically, at least some human ACPA is able to bind 
homocitrulline as well, but the extent of this cross-reactive overlap is unknown since this 
experiment does not quantify the proportion of the polyclonal ACPA response which was also 
able to bind homocitrulline.  It remains unknown whether these cross-reactive antibodies are 
involved in the previously demonstrated arthritogenicity of ACPA (11). 
In human RA, the SE has a very important role in the production of ACPA (5). Therefore, 
this study investigated if homocitrulline could also bind to the SE.  Computer modelling 
suggested homocitrulline could be accommodated by the SE binding pocket.  Again, this 
computer modelling method did not consider local conformational changes, or “induced fitting” 
which would usually occur to optimize binding.  Homocitrullination and the SE were 
investigated further by immunizing transgenic mice which expressed the SE alongside their wild-
type B6 counterpart.  The only differences detected after unmodified or homocitrullinated 
fibrinogen immunization were in DR4 Tg mice 10 days after immunization.  Although not 
statistically significant in any other group, all individual mice immunized with either form of 
fibrinogen did have a greater response upon re-exposure to homocitrullinated protein.   
All mice immunized with fibrinogen (unmodified or homocitrullinated) did generate IgG 
antibodies which bound to homocitrullinated fibrinogen, however only mice immunized with 
homocitrullinated fibrinogen generated IgG antibodies that were homocitrulline specific.  The 
antibodies produced in mice that were immunized with unmodified fibrinogen were likely due to 
differences between native mouse fibrinogen and the human form of the protein which was used 
for immunization, as the sequence homology between the mouse’s native fibrinogen and the 
human fibrinogen is 58%, 87%, and 84% for the alpha, beta, and gamma chains, respectively.  
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The proliferative responses and generation of AHPA in both DR4 Tg and B6 mice indicate that 
the response to homocitrulline is not SE restricted.  In addition to generating anti-
homocitrullinated fibrinogen antibodies, both DR4 Tg and B6 mice also generated ACPA (anti-
JED) when immunized with homocitrullinated fibrinogen, but not when immunized with 
unmodified fibrinogen or even citrullinated fibrinogen.  The generation of ACPA in mice after 
immunization with homocitrulline supports this study’s finding of cross-reactive ACPA in 
human sera as well as Turunen et al.’s observation in rabbits (15).  It also suggests a mechanism 
by which ACPA can be generated independently of the SE.  Specifically, after exposure to 
homocitrullinated protein or peptide, an immune response which binds citrullinated epitopes can 
develop.  Although there are similarities between citrullination and homocitrullination, there are 
important differences too. 
3.2 Homocitrullination vs. Citrullination 
Citrulline and homocitrulline are structurally quite similar as they have the same 
functional, ureido group with only an extra carbon atom that makes the homocitrulline side-chain 
longer (16).  There are, however, major differences in the generation and consequences of the 
two modified amino acids.   
As this study has shown, the modification of human proteins with either citrullination or 
homocitrullination can generate new antigens that are targeted by the immune system and 
promote break in immunological tolerance.  In the case of citrullination, the main proteins which 
are identified in vivo and targeted by ACPA are citrullinated fibrinogen (14, 17), citrullinated 
collagen II (18), citrullinated vimentin (19-20), and citrullinated human α-enolase (21).  Whereas 
citrullination sites can be limited by PAD enzyme specificity and accessibility, chemical 
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homocitrullination at physiological conditions is mainly restricted by isocyanate concentration 
and lysine solvent exposure, so a large percentage of protein lysines can usually be modified (22-
24).  Therefore, there are likely a large number of lysine residues in the human proteome which 
can be modified by homocitrullination and serve as potential immunological antigens. 
Like the generation of citrulline, the process of homocitrullination is influenced 
environmentally.  Numerous factors such as diet, air pollution and cigarette smoking can 
influence serum cyanate levels through multiple mechanisms (25-27) and can therefore, promote 
protein homocitrullination.  Additionally, pathologies which involve carbamylation and have 
their own environmental risks (26, 28-29) could promote increased exposure to homocitrulline.  
Specifically, atherosclerosis could potentially trigger the production of AHPA because 
carbamylated protein accumulation is involved in inflammatory plaque development (26).  
Supporting this idea, coronary artery disease (CAD) due to atherosclerosis has been shown to be 
associated with RA  (30), however, from current literature it is unclear whether CAD is strictly a 
complication (consequence) of RA or if it can be a factor contributing to RA development as 
well.  Perhaps early, undetected atherosclerosis can play a causal role in RA pathogenesis by 
producing an environment that promotes increased exposure to homocitrulline and, thus, the 
generation of AHPA.  CAD as a cause of AHPA production has not yet been demonstrated, 
however, as an alternative hypothesis is that CAD and RA merely often “co-exist” because 
homocitrullination is involved in both pathologies.  In other words, because RA can be promoted 
by an environment that has increased carbamylation and this process also promotes 
atherogenesis, they are just often found together. 
With citrullination, it has been shown that infection from the environment can cause 
exposure to citrulline leading to ACPA production (21).  Bacterial protein α-enolase from 
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Porphyromonas gingivalis has been implicated as a target and initiator of the anti-citrulline 
response through cross-reactive molecular mimicry (21).  Whereas the PAD enzyme responsible 
for citrullination is only known to be expressed in this one bacterium, any bacterium, or bacterial 
antigens which resemble human proteins, could potentially be exposed to urea/cyanate and be 
subsequently carbamylated.  It has even been shown that carbamylation is critical for the 
enzymatic activity of bacterial Class D -Lactamases, which confer antibiotic resistance to many 
common pathogens (31).  Thus, any infection could not only promote inflammatory 
homocitrullination of self proteins (26), but also cause exposure to carbamylated bacterial 
antigens.  This could potentially trigger additional molecular mimicry responses in individuals 
with an adequate genetic background, similar to the citrullination of bacterial α-enolase and 
subsequent production of ACPA in SE positive individuals.   
Previous studies have identified genetic factors which are associated with, and predispose 
people to the development of RA.  These factors include genes encoding MHC class II molecules 
with the SE, PTPN22 variants, and PAD variants and are primarily associated with ACPA 
positive RA (32).  Genetic factors predisposing individuals to the development anti-
homocitrulline responses, if any, still await identification.  As noted previously, at least some 
variants of MPO with different levels of expression do exist and altered MPO expression could 
affect the amount of exposure to homocitrulline.  No MHC genes, however have been linked to 
AHPA production.  Even in the case of citrullination, the presence of identified heritable risk 
factors is not an absolute necessity, as there are RA patients with ACPA that do not express the 
SE.  Since this study demonstrated that the SE is not essential to AHPA production, these 
exceptions to the common model of ACPA production could be explained by homocitrullination 
and citrulline/homocitrulline cross-reactivity. 
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3.3 AHPA/ACPA “cross-reactivity” 
This study and the one by Turunen et al. observed the generation of anti-citrulline 
antibodies after immunization with homocitrullinated antigen (15).  These cross-reactive 
antibodies occurred even in the absence of the SE and, thus, may provide an explanation for the 
presence of ACPA in SE-negative individuals.  Although both of these studies were in animal 
models, the affinity purification of ACPA allowed for the identification of 
citrulline/homocitrulline cross-reactive antibodies in human RA patients. 
Cross-reactive antibodies which can bind both citrullinated and homocitrullinated targets 
could have additional effects on both phases of RA development.  It increases the potential for 
break in immunological tolerance since either modification could generate relevant neo-epitopes 
leading to AHPA/ACPA autoantibody responses.  Secondly, it could also contribute to the 
initiation of joint inflammation since targets in the joint could be generated by both citrullination 
and homocitrullination.  At the very least, since ACPA have been shown to be pathogenic and 
this study has shown at that some ACPA are AHPA, the pathogenic ACPA needs to be further 
characterized.  These observations do suggest that some AHPA may also be involved in RA 
pathogenesis. 
3.4 Homocitrullination in inflammation and RA pathogenesis 
The identification of homocitrulline, AHPA, and cross-reactive antibodies can add 
additional complexity to the current model of RA pathogenesis involving ACPA.  Immune 
responses to homocitrulline can be incorporated into the current model to develop a new, 
potential model for RA pathogenesis involving homocitrullination (Figure 3.1).  To summarize, 
RA research thus far suggests an etiological model for RA by which immunological tolerance 
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can be broken through numerous means.  This process which generates autoantibodies comprises 
what is known as “hit one.”  For example, immunogenic exposure to citrullination could occur in 
the lungs and would be increased by factors such as smoking however, smoking promotes 
homocitrullination as well.  The previous observation that 12% of RA patients have antibodies 
that target MPO and anti-MPO antibodies are more common in patients with lung involvement 
(33), provides further evidence that homocitrullination is also a significant factor during 
inflammation of the lungs. Thus, a response to cigarette-induced citrullination or 
homocitrullination, infection with pathogens that are modified (as with P. Gingivalis), and/or 
exposure to other inflammation-induced (homo)citrullinated self proteins could all potentially 
trigger the production of ACPA and/or AHPA.  ACPA/AHPA production, regardless of its 
origin, may then generate a volatile environment which favours the development of RA and 
awaits the second event, a “spark” to initiate disease. 
It may only be a matter of time until an occurrence such as physical trauma or infection 
triggers inflammation in the joint, or “hit two.”  The inflammation would promote cell death, the 
subsequent release of PAD and MPO, and the accumulation of citrullinated and/or 
homocitrullinated targets in the joints.  With adequate autoantibody responses (ACPA and/or 
AHPA) the generation of these targets in the joint may facilitate arthritogenesis by the formation 
of citrulline and/or homocitrulline immune complexes, recruitment of immune cells, activation 
of complement and the release of pro-inflammatory cytokines (34-35).  Disease could then be 
perpetuated in a cycle whereby inflammation leads to the generation of additional targets which 
promotes more inflammation.  Once such a cycle is sustained chronically, arthritogenesis can 
ensue leading to clinical RA. 
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In summary, based on the findings of this study that AHPA occur specifically in RA and 
some cross-react with citrulline, the current model for RA pathogenesis is more complex than 
that which was previously proposed. This current model now includes immune responses to 
homocitrulline in addition to citrulline as well as possible factors that may be involved in the 
initiation and/or perpetuation of these responses. Many of the steps in this current model await 
validation in human RA and in experimental animal models for this disease. 
3.5 Future Directions 
There is much work which needs to be done do study the involvement of 
homocitrullination in RA and investigate a pathogenic role for AHPA.  First of all, the relevant 
human in vivo targets of AHPA should be investigated, including those that resemble 
citrullinated antigenic regions and are, therefore, involved in cross-reactivity. Furthermore, if 
AHPA are pathogenic, it will need to be demonstrated that anti-homocitrulline immune 
responses precede the onset of RA, as with ACPA production.  This could be done by 
retrospective screening pre-RA serum samples, and by screening sera from the sibling of RA 
patients (since RA siblings can share some genetic and environmental risk factors, they can 
represent a pre-RA state).  Alternative isotypes of AHPA, such as IgA and IgM, should also be 
screened.  Additionally, further screening for AHPA, including in currently “seronegative” 
patients, would benefit from screening with a surrogate homocitrullinated peptide that is 
representative of many homocitrullinated antigens, as CCP2 does with ACPA.  Such studies are 
underway in this laboratory which is further screening the RA cohort utilizing the 
homocitrullinated JED peptide.  Although the antibodies to the similar, citrullinated JED peptide 
have been well characterized, future screening with homocitrullinated JED should test patients 
with other diseases and also include testing RA patient antibody reactivity to a lysinated form of 
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the peptide.  The homocitrullinated JED peptide should also be used to purify AHPA.  This 
would allow us to study their targets and demonstrate a direct arthritogenic role for them in mice, 
as we have done with ACPA. 
Experimental animal models have also been very useful for the study of AHPA.  Mydel 
et al. previously developed a homocitrulline induced arthritis model and we should also try to 
induce disease in mice to test the arthritogenic properties of homocitrullinated fibrinogen, as well 
as the effect of the SE.  Although both DR4 Tg and B6 mice in our studies generated similar 
antibody responses, preliminary characterization of these responses suggest important 
differences between their anti-JED antibody production, with respect to both timing and intensity 
(Figure 3.2).  Therefore, it may be informative to perform studies in which blood is drawn from 
mice at various times throughout the course of immunization and response.  This will help 
determine when the cross-reactive immune response develops in DR4 Tg mice, as even 31 days 
after the primary homocitrullinated fibrinogen immunization, anti-JED was not detected.  
Characterizing the difference between the immune responses of DR4 Tg and B6 mice may 
elucidate a role for the SE in anti-homocitrulline responses.  Also, in Mydel and colleagues’ 
arthritis model it was shown that B6 mice did not develop disease like other mice, but we show 
that they do generate AHPA.  The absence of arthritis in B6 mice leads to a question that can be 
investigated in future experimental studies: is there merely insufficient production of targets in 
joints of these mice or are there specifics in the nature of the immune response which determine 
arthritogenicity?  
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Figure 3.2  Development of ACPA in DR4 Tg and B6 mice immunized with 
homocitrullinated fibrinogen.  ELISA on sera obtained from DR4 Tg and B6 mice after 
immunization with unmodified fibrinogen or homocitrullinated fibrinogen.  Preliminary study 
comparing anti-JED antibody responses in the serum of DR4 Tg (A) and B6 (B) mice 10, 31, or 
90 days post immunization with homocitrullinated fibrinogen.  For day 90 tests, n=6, however, 
for days 10 and 31, n=3 or less.  Therefore, statistical analyses were only performed on day 90 
responses. * = p<0.01. 
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3.6 Conclusions 
This study provides evidence that homocitrulline is involved in RA and it is clear that 
there may be many opportunities for homocitrullination to trigger break in immunological 
tolerance.  It demonstrated that a high proportion of RA patients had antibodies to 
homocitrullinated fibrinogen and that these antibodies were specific to RA, as AHFA were not 
found in normal individuals or patients with other inflammatory rheumatic conditions such as 
Psoriatic Arthritis and SLE.  Furthermore, this study demonstrates that homocitrullination 
provides a mechanism for the generation of neo-epitopes different from those produced by 
citrullination and responses to homocitrulline may constitute a pathway for SE-independent 
ACPA production.  Molecular modelling was used to provide evidence that homocitrulline can 
bind to the SE and this prediction was supported using transgenic mice.  Perhaps in the future, as 
the exponential increase in structural data deposition continues, modelling methods with non-
traditional amino acids can be used to predict auto-epitopes/auto-antigens which are potentially 
immunogenic after post-translational modification.   
 It is unknown whether citrullination and/or homocitrullination are critical for the 
development of RA in some patients.  The observation that human ACPA precedes disease, 
combined with animal research involving citrullination does suggest a pathogenic role for these 
autoantibodes.  Considering current research on homocitrullination in RA, its similarities with 
citrullination, and its aforementioned strong link with environmental influence (including 
smoking, and its involvement in the known complication of RA, atherosclerosis (30, 36-37)), it is 
reasonable to anticipate that AHPA is also involved in RA pathogenesis.  Furthermore, evidence 
implicates ACPA as arthritogenic and we have shown that at least some of these antibodies are 
AHPA as well.  The existence of these cross-reactive antibodies demands further investigation 
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into the target specificity of auto-antibodies in RA.  As previously mentioned, ACPA could be 
further classified regarding binding properties to homocitruline and/or the origin of the immune 
response (whether triggered by citrullination or homocitrullination). If antibody responses to 
citrulline and homocitrulline are indeed arthritogenic, important questions remain: which 
antibodies are pathogenic?  Is it the specificity of the target antigen, the quantity and diversity of 
the response, and/or merely the binding affinity to available targets in the arthritic joint which are 
important in determining arthritogenicity and clinical disease progression.  As Turunen et al. 
reported “homocitrulline as a confounder in citrulline detection” (15), this study suggests 
homocitrulline is also a confounder of anti-citrulline antibody responses in rheumatoid arthritis. 
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Alpha-Chain 
 1 MFSMRIVCLVLSVVGTAWTADSGEGDFLAEGGGVZGPZVVEZHQSACXDS  
51DWPFCSDEDWNYKCPSGCZMXGLIDEVNQDFTNZINXLXNSLFEYQXNNX 
101DSHSLTTNIMEILZGDFSSANNZDNTYNZVSEDLZSZIEVLKRXVIEXVQ 
151HIQLLQXNVRAQLVDMXRLEVDIDIKIZSCZGSCSZALAZEVDLXDYEDQ 
201QXQLEQVIAXDLLPSZDZQHLPLIXMXPVPDLVPGNFXSQLQXVPPXEWXA  
251LTDMPQMRMELERPGGNEITRGGSTSYGTGSETESPRNPSSAGSWNSGSS 
301GPGSTGNRNPGSSGTGGTATWKPGSSGPGSTGSWNSGSSGTGSTGNQNPG 
351SPRPGSTGTWNPGSSERGSAGHWTSESSVSGSTGQWHSESGSFRPDSPGS 
401GNAZPNNPDWGTFEEVSGNVSPGTZZEYHTEXLVTSXGDXELZTGXEXVT  
451SGSTTTTZZSCSXTVTXTVIGPDGHXEVTXEVVTSEDGSDCPEAMDLGTL 
501SGIGTLDGFZHZHPDEAAFFDTASTGKTFPGFFSPMLGEFVSETESZGSE 
551SGIFTNTXESSSHHPGIAEFPSZGXSSSYSXQFTSSTSYNZGDSTFESXS 
601YXMADEAGSEADHEGTHSTXZGHAKSZPVRGIHT  
Beta-Chain 
1QGVNDNEEGFFSAZGHZPLDXXZEEAPSLZPAPPPISGGGYZAZPAXAAA 
51TQXXVERXAPDAGGCLHADPDLGVLCPTGCQLQEALLQQEZPIZNSVDEL  
101NNNVEAVSQTSSSSFQYMYLLXDLWQXZQXQVXDNENVVNEYSSELEXHQ 
151LYIDETVNSNIPTNLZVLZSILENLZSKIQXLESDVSAQMEYCRTPCTVS 
201CNIPVVSGXECEEIIZXGGETSEMYLIQPDSSVXPYZVYCDMNTENGGWT  
251VIQNZQDGSVDFGZXWDPYXQGFGNVATNTDGXNYCGLPGEYWLGNDXIS 
301QLTRMGPTELLIEMEDWXGDXVXAHYGGFTVQNEANXYQISVNXYRGTAG 
351NALMDGASQLMGENRTMTIHNGMFFSTYDZDNDGWLTSDPZXQCSXEDGG 
401GWWYNRCHAANPNGZYYWGGQYTWDMAKHGTDDGVVWMNWXGSWYSMRXM 
451SMXIRPFFPQQ 
Gamma-Chain 
   1MSWSLHPRNLILYFYALLFLSSTCVAYVATRDNCCILDEZFGSYCPTTCG   
51IADFLSTYQTXVDKDLQSLEDILHQVENKTSEVXQLIXAIQLTYNPDESS 
101XPNMIDAATLXSRXMLEEIMXYEASILTHDSSIZYLQEIYNSNNQXIVNL 
151XEKVAQLEAQCQEPCXDTVQIHDITGXDCQDIANXGAXQSGLYFIXPLXA 
201NQQFLVYCEIDGSGNGWTVFQXZLDGSVDFXXNWIQYXEGFGHLSPTGTT 
251EFWLGNEKIHLISTQSAIPYALZVELEDWNGZTSTADYAMFXVGPEADXY 
301ZLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEG 
351NCAEQDGSGWWMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKT 
401ZWYSMXXTTMXIIPFNZLTIGEGQQHHLGGAXQAGDV  
 
Appendix 3.  In vitro homocitrullination and citrullination sites on 
human.fibrinogen as determined by mass spectrometry.  Amino acid 
sequence of fibrinogen.  Black X represents sites where homocitrulline was 
detected and black Z represents sites where citrulline was detected.  Pale 
colored R or K represents Arg or Lys for which no data was obtained. Underlining 
represents homocitrullinated peptides which are predicted to bind to the SE. 
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